Abstract
The ventral striatum-nucleus accumbens network has been associated with impulsive behavior in subjects with early cognitive impairment; in Alzheimer's disease (AD) modifications of basal ganglia have been also demonstrated. Moreover, the increase of EEG alpha3/alpha2 frequency power ratio has been investigated as EEG marker in subjects with mild cognitive impairment (MCI) who will develop AD. In the present study we have detected the relationship between upper alpha/low alpha ferquency power ratio and specific gray matter (GM) changes in the basal ganglia in subjects with MCI. Electroencefalographic (EEG) recording and high resolution 3D magnetic resonance imaging (MRI) were taken in 74 MCI subjects. In each subject the alpha3/alpha2 EEG frequency power ratio was estimated as EEG biomarker. Three groups were obtained according to increasing tertiles values of the biomarker. Through the Voxel Based Morphometry (VBM) technique, GM density differences between groups were evaluated. Results show that subjects with lower a3/a2 and middle a3/a2 ratio ratio showed greater gray matter reduction in the Nucleus Accumbens and the head of Caudate Nucleus as compared to subjects with higher a3/a2 ratio. Our study indicates that the a3/a2 frequency power ratio was associated with increase of grey matter density inside the impulsivity network of MCI patients more likely develop AD.
Keywords: Basal ganglia, EEG, impulsive control disorder, mild cognitive impairment, MRI, VBM.
Current Alzheimer Research
Title:EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment.
Volume: 11 Issue: 2
Author(s): Davide V. Moretti, Donata Paternico, Giuliano Binetti, Orazio Zanetti and Giovanni B. Frisoni
Affiliation:
Keywords: Basal ganglia, EEG, impulsive control disorder, mild cognitive impairment, MRI, VBM.
Abstract: The ventral striatum-nucleus accumbens network has been associated with impulsive behavior in subjects with early cognitive impairment; in Alzheimer's disease (AD) modifications of basal ganglia have been also demonstrated. Moreover, the increase of EEG alpha3/alpha2 frequency power ratio has been investigated as EEG marker in subjects with mild cognitive impairment (MCI) who will develop AD. In the present study we have detected the relationship between upper alpha/low alpha ferquency power ratio and specific gray matter (GM) changes in the basal ganglia in subjects with MCI. Electroencefalographic (EEG) recording and high resolution 3D magnetic resonance imaging (MRI) were taken in 74 MCI subjects. In each subject the alpha3/alpha2 EEG frequency power ratio was estimated as EEG biomarker. Three groups were obtained according to increasing tertiles values of the biomarker. Through the Voxel Based Morphometry (VBM) technique, GM density differences between groups were evaluated. Results show that subjects with lower a3/a2 and middle a3/a2 ratio ratio showed greater gray matter reduction in the Nucleus Accumbens and the head of Caudate Nucleus as compared to subjects with higher a3/a2 ratio. Our study indicates that the a3/a2 frequency power ratio was associated with increase of grey matter density inside the impulsivity network of MCI patients more likely develop AD.
Export Options
About this article
Cite this article as:
Moretti V. Davide, Paternico Donata, Binetti Giuliano, Zanetti Orazio and Frisoni B. Giovanni, EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment., Current Alzheimer Research 2014; 11 (2) . https://dx.doi.org/10.2174/156720501102140313155546
DOI https://dx.doi.org/10.2174/156720501102140313155546 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Predictive Model of the Prevalence of Delirium in Elderly Subjects Admitted to Nursing Homes
Endocrine, Metabolic & Immune Disorders - Drug Targets Abnormal Functional and Structural Asymmetry as Biomarker for Schizophrenia
Current Topics in Medicinal Chemistry HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Cholinesterase Inhibitors: From Weapons, to Pesticides, to Cognition Enhancing Drugs
Current Enzyme Inhibition Vascular C-Reactive Protein in the Pathogenesis of Coronary Artery Disease:Role of Vascular Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Spinal Microvascular Expression of PV-1 is Associated with Inflammation, Perivascular Astrocyte Loss, and Diminished EC Glucose Transport Potential in Acute SCI
Current Neurovascular Research Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology UGT1A1 Mediated Drug Interactions and its Clinical Relevance
Current Drug Metabolism Juvenile Neuronal Ceroid-Lipofuscinosis (Batten Disease): A Brief Review and Update
Current Molecular Medicine Applying Melanopic Lux to Measure Biological Light Effects on Melatonin Suppression and Subjective Sleepiness
Current Alzheimer Research Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Automatic Detection of Cognitive Impairments through Acoustic Analysis of Speech
Current Alzheimer Research The Role of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis. Where are we Now?
Recent Patents on CNS Drug Discovery (Discontinued) Hypothermia and Alzheimer's Disease Neuropathogenic Pathways
Current Alzheimer Research Possible Involvement of Advanced Glycation End-Products (AGEs) in the Pathogenesis of Alzheimers Disease
Current Pharmaceutical Design Herbal Medicine as an Alternative Treatment in Autism Spectrum Disorder: A Systematic Review
Current Drug Metabolism Disease State, Age, Sex, and Post-Mortem Time-Dependent Expression of Proteins in AD vs. Control Frontal Cortex Brain Samples
Current Alzheimer Research Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery